ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

daprodustat

Also written as “GSK1278863”, “Daprodustat” and “Daprodustat (GSK1278863)”.

Its studies are mostly in Anemia · Diabetic Foot · Peripheral Vascular Diseases · Tendon Injuries, led by 2 companies.

Drug pageGSK1278863: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 2, 201633 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only320 open or runningphase 3since Jun 2, 2016Jun 16, 2011none ahead
Qilu Pharmaceutical11 open or runningphase 3since Dec 10, 2025Dec 10, 2025May 2027phase 3 · NCT07300111

Also a collaborator on its studies: Q2 Solutions, Quintiles, HemoCue and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Qilu Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named daprodustatINNProposed as its International Nonproprietary Name in WHO's List 113 · before, GSK1278863
  2. Dec 10, 2025First study: phase 3 study in AnemiaFirst studyNCT07300111 · 100 planned

Ahead

  1. May 2027Primary completion: phase 3 study in AnemiaNCT07300111

TargetBeta

“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
roxadustatruleAstellas Pharmaphase 447

Studies

The one study Qilu Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07300111Anemia3Not yet recruitingMay 2027100

How it is read

Names in the registry

  • “GSK1278863”, 15 entries
  • “Daprodustat”, 9 entries
  • “Daprodustat (GSK1278863)”, 2 entries
  • “Daprodustat tablets”, 1 entry
  • “1 to 4 mg tablets of GSK1278863”, 1 entry

Codes read as this program: GSK1278863.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.